Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
Rhea-AI Summary
Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on innovative cancer therapies, has scheduled its second quarter 2025 financial results announcement and business update for August 4, 2025.
The company will host a conference call and live audio webcast at 4:30 p.m. ET on the same day. Investors can access the event through the company's website or by dialing 800-590-8290 (domestic) or 240-690-8800 (international). A replay will be available on Syndax's website for 90 days after the call.
Positive
- None.
Negative
- None.
News Market Reaction 38 Alerts
On the day this news was published, SNDX declined 0.62%, reflecting a mild negative market reaction. Argus tracked a peak move of +10.1% during that session. Our momentum scanner triggered 38 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $915M at that time. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2025 financial results and provide a business update on Monday, August 4, 2025.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, August 4, 2025.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax2Q25
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://sndx-2q25.open-exchange.net
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
When will Syndax (NASDAQ: SNDX) report Q2 2025 earnings?
How can investors access Syndax's Q2 2025 earnings call?
Where can I find the replay of Syndax's Q2 2025 earnings call?
What will be discussed in Syndax's Q2 2025 earnings call?
